Dmitrii S.
Bolotin
*a,
Marina Ya.
Demakova
a,
Anton A.
Legin
b,
Vitaliy V.
Suslonov
c,
Alexey A.
Nazarov
d,
Michael A.
Jakupec
*b,
Bernhard K.
Keppler
b and
Vadim Yu.
Kukushkin
a
aInstitute of Chemistry, Saint Petersburg State University, Universitetskaya Nab., 7/9, Saint Petersburg, Russian Federation. E-mail: d.s.bolotin@spbu.ru
bInstitute of Inorganic Chemistry and Research Platform “Translational Cancer Therapy Research”, University of Vienna, Währinger Strasse 42, A-1090 Vienna, Austria. E-mail: michael.jakupec@univie.ac.at
cCenter for X-ray Diffraction Studies, Saint Petersburg State University, Universitetskii Pr., 26, Saint Petersburg, Russian Federation
dDepartment of Chemistry, Moscow State University, Leninskie Gory, 1,3, Moscow, Russian Federation
First published on 1st June 2017
The reaction of cis-[PtCl2(Me2O)2] with 1 equiv. of each of the amidoximes RC(NH2)NOH in neutral media in MeOH results in the formation of complexes cis-[PtCl2{RC(NH2)OH}(Me2O)] (5 examples; 83–98% isolated yields). In the presence of 2 equiv. of NaOH in MeOH solution, the reaction of cis-[PtCl2(Me2O)2] with 1 equiv. of each of the amidoximes RC(NH2)NOH leads to [Pt{RC(H)N}(Me2O)2] (7 examples; 74–95% isolated yields). All new complexes were characterized by C, H, and N elemental analyses, HRESI+-MS, IR, 1H, 13C{1H}, and CP-MAS TOSS 13C{1H} NMR spectroscopies, and additionally by single-crystal XRD (for seven species). The cytotoxic potency of six compounds was determined in the human cancer cell lines CH1/PA-1, A549, SK-BR-3, and SW480. Generally, the second class of complexes containing chelating amidoximato ligands shows much higher cytotoxicity than the non-chelate amidoxime analogs, despite the lack of easily exchangeable chlorido ligands. Especially, the complex [Pt(p-CF3C6H4C(H)N)(Me2O)2] displays a remarkable activity in the inherently cisplatin resistant SW480 cell line (0.51 μM vs. 3.3 μM).
The classic structure–activity relationships for platinum compounds are based on platinum being present as PtII or PtIV centers with two cis-configured leaving groups and two stable am(m)ine ligands coordinated to the metal.4 While the complexes are supposed to remain in their original composition during administration and circulation in the bloodstream, the low chloride concentration in the cell allows a chlorido/aqua exchange to occur. Sequential replacement of the leaving ligands leads to positively charged complexes that interact initially electrostatically with the negatively charged phosphate backbone of DNA before a second step of ligand exchange reactions leading to the platination of DNA. Platinum is found most commonly attached to guanine residues in the major groove and to a lesser extent to adenine moieties. In particular, the presence of adjacent guanines residues has been found to be advantageous to support the binding event between the platinum center and DNA, leading to DNA lesions that cannot be repaired easily and trigger apoptosis.5
The nature of the leaving ligand(s) has been shown to be crucial for reducing the side effects, and this has especially been demonstrated for the second and third generation compounds, carboplatin and oxaliplatin, which feature the negatively charged cyclobutanedicarboxylato and oxalato ligands, respectively.5c,6 However, there are also neutral ligands that can easily be substituted under physiological conditions. Ligands such as DMF and (CH3)2SO have been widely used in the preparation of complexes and their metal species are often identified as intermediates.6c,7 Furthermore, (CH3)2SO is found in the ruthenium-based anticancer agent NAMI-A, which was studied for its antimetastatic effects in two clinical trials before being ruled out recently.8
More recently, interest has grown in the so-called rule-breaker compounds that do not follow the classic structure–activity relationships recognized for the established anticancer agents and their close analogs. Such rule-breakers are for example trans-configured PtII complexes, but also multinuclear platinum compounds have been investigated and the latter even reached clinical trials due to their potential to overcome cisplatin resistance at least in cell culture. Such non-classic compounds have been suggested to interact with DNA in a different manner from the platinum cis-complexes and thereby would have a different mode of action that may help to overcome the drawbacks of platinum-based chemotherapy.9
These considerations led us to the design and preparation of amidoxime and amidoximato PtII complexes. Oxime complexes have been shown in the past by us and others to exhibit anticancer activity in an in vitro setting.10 Moreover, organic compounds featuring the amidoxime functional group have also been shown to be anticancer active.11 The synthesis of the platinum complexes was performed starting from the platinum precursor cis-[PtCl2(Me2O)2] and the amidoximes in methanol and in the presence of NaOH. Depending on the conditions, either the [PtCl2(amidoxime-κ1-Noxime)(Me2O)] or the [Pt(amidoximato-κ2-O,Namide)(Me2O)2] complexes were obtained. The cytotoxicity of three species of each class was screened in the human cancer cell lines CH1/PA-1, A549, SK-BR-3, and SW480, where the MTT assay revealed only marginal activity for the three amidoxime complexes, moderate activity for two of three amidoximato complexes, but a remarkably high cytotoxic potency for the complex bearing a p-trifluoromethylbenzamidoximate ligand, especially in the SW480 cell line. All our studies are consistently disclosed in sections that follow.
The four known amidoxime complexes feature exclusively Noxime-ligated amidoximes and the NH2 moiety of amidoxime ligands is unligated to the platinum(II) stipulating the amidoximes play a role of conventional oxime ligand. No examples of platinum(II) amidoxime complexes featuring the Namide-bound ligands were previously reported. Moreover, as analysis of literature data indicated,13 amidoxime species have at least four types of ligation in mononuclear complexes (Fig. 2) and the selective preparation of amidoxime complexes with an exact coordination mode is still an open problem.
Fig. 2 Coordination modes of amidoximes in their mononuclear complexes.13 |
The generation of type II complexes proceeds either with oxophilic metal centers or in the presence of a base due to the deprotonation of the O atom resulting in an increase of its nucleophilicity. The coordination of amidoximes by the O atom in basic media commonly is accompanied by the deprotonation of the NH2 moiety with consequent chelation of the metal center giving type IV complexes. Type III complexes are mostly realized at electron-deficient metal centers, viz., early transition metals or f-elements.
In this work, we decided to comprehensively investigate the preparation of amidoxime platinum(II) complexes with a particular purpose of finding selective routes for the generation of complexes with a well-defined coordination mode of amidoxime ligands. We planned the selective preparation of the complexes of types I, II, and IV by variation of the acidity of the reaction mixtures, whereas complexes of type III are hardly accessible at a rather electron-rich platinum(II) center. Previously, it was reported that the amidoxime OH group can be effectively deprotonated by NaOH in alcohol media15 and, concurrently, amidoximes can be protonated at the oxime N atom by strong acids.13 Because of these reasons, we decided to use NaOH and TfOH to vary the acidity of the reaction mixtures and to employ MeOH as a solvent.
Scheme 1 Generation of amidoxime and amidoximate platinum(II) complexes. a Analytical data are not sufficient for full characterization. |
Complexes 3a–b and 3d–f give satisfactory C, H, and N elemental analyses for the proposed formulas. These species were also characterized by HRESI+-MS, IR, 1H, 13C{1H}, and CP-MAS TOSS 13C{1H} NMR spectroscopies, and additionally by X-ray diffraction (XRD). Compounds 3a–b and 3d–f are stable in the solid state at RT and upon heating decompose in the range of 142–185 °C.
A characteristic feature of the positive-mode high-resolution ESI mass spectra of 3a–b and 3d–f is the availability of sets of peaks related to fragmentation and quasi-ions corresponding to [M − 2Cl + H]+, [M − Cl]+, [M − Cl − H + Na]+, [M + Na]+, [M + K]+, [2M − 2Cl − 2H + Na]+, [2M − Cl]+, [2M + Na]+, [2M + K]+, and [3M − 2Cl − 2H + Na]+.
In the IR spectra of 3a–b and 3d–f, we observed two or three medium-strong to very strong bands in the region of 3480–3215 cm−1, which can be attributed to the O–H and N–H stretches, and a set of weak to medium bands at 3187–2785 cm−1 assignable to the C–H stretches.18 All spectra also display one very strong band in the 1663–1655 cm−1 region specific for the ν(CN) of the amidoxime moiety13 and one medium to very strong band at 1138–1105 cm−1 characteristic of the ν(SO) stretches of sulfur-bound sulfoxides.19 In addition, the spectrum of 3f displays two very strong bands at 1520 and 1346 cm−1 specific for asymmetric and symmetric ν(NO) bands of the NO2 moiety.18
Complexes 3a–b and 3d–f are almost insoluble in the common deuterated organic solvents (CDCl3, CD2Cl2, (CD3)2CO, and D2O) apart from (CD3)2SO and CD3OD. In (CD3)2SO, the exchange of ligated (CH3)2SO with the solvent molecules occurs for 5 min, and therefore the spectra were recorded in CD3OD. A characteristic feature of the 1H NMR spectra is the non-equivalence of the methyl groups of the Me2SO ligand. Thus, the spectra of 3a–b exhibit one unresolved broad singlet at 3.45 ppm (3a) or two singlets at 3.46 and 3.44 ppm (3b), whereas the spectra of 3d–f, derived from aromatic amidoximes 2d–f, display two singlets at 3.42–3.37 and 2.83–2.59 ppm. In 3d–f relatively to 3a–b, the high-field shift (0.59–0.78 ppm) of one of the methyl groups of the Me2SO ligand should be associated with the shielding effect of the aromatic rings (see X-ray structure determinations).
The 13C{1H} NMR spectra in CD3OD (3a–b and 3d–e) exhibit a low-field signal at 162.29–157.89 ppm, which is attributed to the CNOH carbon of the amidoxime moiety,13 whereas in the high-field the spectra display two singlets attributed to the methyl groups of the Me2SO ligand at 43.31–42.95 and 42.98–42.55 ppm, which agree well with the two singlets observed in the 1H NMR spectra. Compound 3f exhibits poor solubility in CD3OD leading to a poor-quality 13C{1H} NMR spectrum even with long acquisition time and it was characterized by solid-state CP-MAS TOSS 13C{1H} NMR. The spectrum displays one singlet at 155.19 ppm from the C atom of the carbamidoxime moiety and four singlets of the methyl groups of Me2SO ligand in the region of 46.59–40.18 ppm. Duplication of signals related to the Me2SO ligand is probably due to two different conformations of 3f in the solid sample.
Complexes 4c–g give satisfactory C, H, and N elemental analyses for the proposed formulas. These species were also characterized by HRESI+-MS, IR, 1H, and 13C{1H} NMR spectroscopies, and additionally by XRD (for 4c and 4f). Compounds 4c–g are stable in the solid state at RT and upon heating decompose in the range of 189–218 °C.
A characteristic feature of the positive-mode high-resolution ESI mass spectra of 4c–g is the availability of sets of peaks related to fragmentation [M − Me2SO + H]+ (4e) and the quasi-ions [M + H]+ and [M + Na]+. The availability of a high-intensity set of peaks from [M + H]+, which was not observed for 3a–b and 3d–f, is probably due to protonation of the basic N atom of the oxime group, which is occupied by the platinum center in 3a–b and 3d–f.
In the IR spectra of 3c–g, we observed from one to three weak-medium to medium bands in the region of 3420–3295 cm−1, which can be attributed to the N–H stretches, and a set of weak to medium bands at 3013–2870 cm−1 assignable to the C–H stretches.18 All spectra also display one weak to medium band in the 1638–1597 cm−1 region assigned to the ν(CN) of the amidoximate moiety13 and one strong to very strong band at 1130–1126 cm−1 characteristic of the ν(SO) of sulfur-bound sulfoxides.19 In addition, the spectrum of 4f displays two strong bands at 1516 and 1341 cm−1 specific for asymmetric and symmetric NO stretches of the NO2 moiety.18
Complexes 3c–g are soluble in the most common deuterated organic solvents, but in (CD3)2SO, the exchange of ligated (CH3)2SO with the solvent molecules was observed for 15 min and therefore their 1H NMR spectra were recorded in CDCl3. A characteristic feature of the 1H NMR spectra is the availability of a singlet flanked with satellites (JPtH2 = 88–112 Hz) in the region 5.52–4.85 ppm assignable to the amide H. Another characteristic feature is the presence of two singlets with satellites (JPtH3 = 12–24 Hz) related to two Me2SO ligands.
The 13C{1H} NMR spectra in CDCl3 (4c–e and 4g) exhibit a low-field signal at 168.94–159.19 ppm, which is attributed to the HN–CNO carbon of the amidoximate moiety,13 whereas in the high-field, the spectra display two singlets flanked with satellites (4c–e: JPtC2 = 32–39 Hz; 4g: not observable due to low solubility) attributed to the methyl groups of the Me2SO ligand at 47.02–46.96 and 46.39–46.23 ppm. Compound 4f exhibits poor solubility in CDCl3 and in other common deuterated solvents leading to a poor-quality 13C{1H} NMR spectrum for 12 h acquisition and it was characterized by solid-state CP-MAS TOSS 13C{1H} NMR. The spectrum of 4f displays three characteristic singlets at 161.75, 45.47, and 41.01 ppm assignable to the HN–CNO carbon and two OS(CH3)2 carbons.
Fig. 3 Molecular structures of 3f (left) and 4f (right) showing the atomic numbering scheme. Thermal ellipsoids are given at the 50% probability level. |
In amidoxime and amidoximate ligands of 3a–b, 3d·MeOH, 3e–f, 4c, and 4f, the O(1)–N(1), N(1)–C(1), and N(2)–C(1) distances are equal to 1.38(2)–1.437(6), 1.289(8)–1.309(4), and 1.326(5)–1.365(8) Å, respectively, and these values are specific for amidoxime and amidoximate complexes.13 The inspection of bond length values indicate that O(1)–N(1) is a single bond,18 whereas the N(1)–C(1) and N(2)–C(1) bonds have transitive orders between single and double bonds, but the former is rather a double bond and the latter has more single bond character.18
Owing to steric reasons, in 3d·MeOH and 3e–f, the torsion angles between the aromatic rings and the carbamidoxime moiety are in the range of 49.76–54.92°, which indicates partial delocalization between these two groups. In 4f, the torsion angles between the groups in two crystallographically independent types of molecules are 15.60 and 22.04° favoring π-conjugation. In 3d·MeOH and 3e–f, one of the methyl groups of the ligated Me2SO is located above a plane of the aromatic rings with the C6⋯C(4) distances equal 3.642(4)–3.716(5) Å, which lead to a high-field shift of the CH3 signals in the 1H NMR spectra.
The crystal structures of 3a–b and 3e–f display intermolecular H-bonds between the oxygen atom of the Me2SO ligand and one of the amide hydrogen atoms [O(2)⋯N(2) 2.914–2.961 Å; O(2)⋯H–N(2) 139.71–152.21°]. In addition, in 3a an intermolecular H-bond was observed between the Cl(1) ligand and the HO moiety of the amidoxime ligand [Cl(1)⋯O(1) 3.117 Å; Cl(1)⋯H–O(1) 174.01°], whereas an intermolecular H-bond between the O atom of the Me2SO ligand and the HO moiety of the amidoxime ligand was found in 3b [O(1)⋯O(2) 2.749 Å; O(1)–H⋯O(2) 171.62°]. In 3d·MeOH, three intermolecular H-bonds were observed, viz. O(1)–H⋯O(3) [O(1)⋯O(3) 2.664 Å; O(1)–H⋯O(3) 176.31°], N(2)–H⋯O(3) [N(2)⋯O(3) 2.975 Å; N(2)–H⋯O(3) 162.83°], and O(3)–H⋯O(2) [O(3)⋯O(2) 2.765 Å; O(3)–H⋯O(2) 161.44°].
1H NMR monitoring of the reaction between 2g and 1 in CD3OD at RT or 65 °C indicates the formation of a broad spectrum of unidentified products. In the HRESI+-MS spectra, sets of peaks associated with 3g (503.9614 [M + Na]+, calcd 503.9626; 926.9742 [2M − Cl]+, calcd 926.9782; 984.9367 [2M + Na]+, calcd 984.9363) were found, but all these peaks could also be due to the isomeric [PtCl2(Me2O){C5H4C(NH2)NOH}]; the coordination mode of the amidoxime ligand is typical for 4-pyridyl carbamidoxime.13 Owing to the similar solubilities of the compounds in the mixture and their decomposition on silica gel, no pure components were isolated. We associate the formation of the mixture of products with the availability of an additional nucleophilic center, i.e. the pyridyl N atom, which competes with the amidoxime N atom in coordination to the metal center and provides some side-reactions.
No formation of the bis-amidoxime complexes [PtCl2{RC(NH2)OH}2] or [PtCl{RC(NH2)OH}2(Me2O)]Cl was detected even in the presence of 10-fold excess of any one of the amidoximes 2a–g relative to 1 in MeOH at RT or at 65 °C for 10 d. Under these conditions, only the formation of 3a–b and 3d–f was detected and these complexes were isolated in 70–85% yields and no sets of peaks related to the bis-amidoxime complexes were observed in HRESI+-MS spectra. In addition, all attempts of the generation of [PtCl{RC(NH2)OH}2(Me2SO)](OTf) by treatment of 3a–b or 3d–f with 1 equiv. of AgOTf in MeOH from −20 to 65 °C were unsuccessful due to the formation of broad mixtures of products that we failed to separate.
The amidoximes featuring strong donor substituents R (R = 4-morpholyl, p-Me2NC6H4, and p-MeOC6H4) react with 1 at various temperatures in the range from 0 to 65 °C in MeOH, Me2CO, and CHCl3 giving a broad spectrum of unidentified products and they could not be utilized in the reactions described above.
No. | IC50 (μM) | |||
---|---|---|---|---|
CH1/PA-1 | SW480 | A549 | SK-BR-3 | |
a Data taken from ref. 10b. | ||||
3b | 130 ± 44 | >320 | >320 | 202 ± 103 |
3d | 150 ± 37 | 272 ± 72 | >320 | 240 ± 78 |
3e | 129 ± 26 | 157 ± 30 | >320 | 227 ± 21 |
4c | 19 ± 5 | 19 ± 4 | 99 ± 7 | 18 ± 2 |
4d | 11 ± 1 | 7.9 ± 0.4 | 78 ± 6 | 13 ± 1 |
4e | 0.96 ± 0.25 | 0.51 ± 0.13 | 30 ± 4 | 2.3 ± 0.3 |
Cisplatina | 0.14 ± 0.3 | 3.3 ± 0.4 | 1.3 ± 0.4 | — |
Complexes 3b and 3d–e display very low activity in these cell lines with IC50 values consistently exceeding 100 μM and are hence about two orders of magnitude less active than the prototypic oxime complex cis-[PtCl2(Me2COH)2] containing two acetoxime ligands in CH1/PA-1 and SW480 cells.23 In contrast, most IC50 values of chelate congeners 4c–e (except for A549 cells) are in the low micromolar to submicromolar range and hence at least one order of magnitude lower than those of the former complexes. In particular, complex 4e bearing a p-trifluoromethylbenzamidoximate ligand shows by far the highest cytotoxic potency and displays a remarkable activity in the inherently cisplatin resistant SW480 cell line (0.51 μM vs. 3.3 μM, Table 1). This indicates that the trifluoromethyl substituent in the para position, which differentiates 4e from 4d (bearing an unsubstituted phenyl group), is highly favorable for cytotoxicity, enhancing it by another order of magnitude in CH1/PA-1 and SW480 cells, whereas no such effect could be observed for 3e in comparison to 3d.
The results for both classes of complexes are surprising, insofar as the presence of two readily exchangeable chlorido ligands in the cis position is not associated with high cytotoxicity here, whereas the lack of easily exchangeable ligands is. An opposite relationship between the activity of the chelate and open-chain forms was in fact previously shown for the sister class of platinum(II) compounds featuring 1,3-dihydroxyacetone oxime ligands.10c In contrast, one of the open-chain and not a chelate species had been shown to overcome the resistance of SW480 cells to cisplatin. It has to be borne in mind, however, that the two classes studied here are no such close analogs that can be converted into each other by (de)protonation and chloride subtraction/addition, but additionally differ by the presence of a second dimethyl sulfoxide instead of a chlorido ligand in the amidoximato complexes. In line with current knowledge on platinum drugs, it is reasonable to assume that opening of the chelates is a prerequisite for high biological activity of the amidoximato complexes and that this opening may be favored by trans effects exerted by the sulfur donors destabilizing the opposite bonds.
These results are intriguing in the light of the known impact of dimethyl sulfoxide on the biological activity of platinum compounds. When used as a solvent for cisplatin or carboplatin (both having two chlorido ligands), (CH3)2SO causes a profound deactivation of the drug due to ligand exchange reactions, whereas the activity of oxaliplatin (having a chelating oxalate as a leaving group) remains virtually unaffected or is slightly enhanced for unknown reasons.19 A report on the antiproliferative activity of platinum(II) complexes of the type [PtL2(Me2O)2] (where L2 is a chelating ligand or L is a monodentate ligand) against a set of human cancer cell lines clearly indicates low activity of these complexes relative to non-dimethyl sulfoxide analogs.24 On the other hand, (CH3)2SO ligands are supposed to favor the cellular uptake of metal complexes, and the increase in activity of 4c–e might therefore also arise from the additional (CH3)2SO ligand in this group, which may enhance the permeability of the drugs through lipid membranes.25
The cytotoxic properties of the novel complexes of both types were examined in four human cancer cell lines (CH1/PA-1, SW480, A549, and SK-BR-3). It was found that chelate amidoximate complexes are significantly more cytotoxic than the open-chain species. Notably, complex 4e displays appreciably enhanced cytotoxicity in the intrinsically cisplatin-resistant SW480 cell line as compared to cisplatin, indicating a promising potential to overcome at least some forms of cisplatin resistance.
Further development of selective preparation of amidoxime complexes of other metals and studies of the cytotoxic activity of complexes featured ligands that structurally similar to amidoximes (amidrazones and hydroxamic acids) are underway in our group.
3f. Yield: 98% (102.9 mg). Mp: 183 °C (dec). Anal. calcd for C9H13N3Cl2O4PtS: C, 21.65; H, 3.52; N, 6.39. Found: C, 21.73; H, 3.41; N, 6.48. HRESI+-MS (MeOH, m/z): 453.0172 ([M − 2Cl − H]+, calcd 453.0191), 489.9923 ([M − Cl]+, calcd 489.9946), 547.9517 ([M + Na]+, calcd 547.9524), 1014.9577 ([2M − Cl]+, calcd 1014.9580), 1072.9157 ([2M + Na]+, calcd 1072.9161). IR (KBr, selected bonds, cm−1): 3439(s), 3335(s) ν(O–H) and ν(N–H); 3185(m), 3107(w), 3079(w), 3001(w-m), 2918(w-m) ν(C–H); 1661(vs) ν(CN); 1520(vs) ν(NO)as; 1346(vs) ν(NO)s; 1136(s) ν(SO). 1H NMR (CD3OD, δ): 8.43 (d, 2H, CH), 8.19 (d, 2H, CH), 3.42 (s, 3H, CH3), 2.83 (s, 3H, CH3). CP-MAS TOSS 13C{1H} NMR (δ): 155.19 (C(NH2)NOH), 149.60, 148.08, 146.40, 138.11, 133.02, 129.73, 123.36, 122.12 (Ar), 46.59, 44.17, 42.66, 40.18 (s, CH3). Crystals of 3f suitable for X-ray diffraction were obtained by slow evaporation of MeNO2 solution at RT in air.
4f·H2O. Yield: 95% (104.1 mg). Mp: 210 °C (dec). Anal. calcd for C11H17N3O5PtS2·H2O: C, 24.09; H, 3.49; N, 7.66. Found: C, 23.99; H, 3.54; N, 7.65. HRESI+-MS (m/z): 531.0306 ([M + H]+, calcd 531.0331), 553.0104 ([M + Na]+, calcd 553.0150). IR (KBr, selected bonds, cm−1): 3414(m), 3335(m) ν(N–H); 2990(m), 2913(m) ν(C–H); 1597(m) ν(CN); 1516(m-s) ν(NO)as; 1341(s) ν(NO)s; 1130(vs) ν(SO). 1H NMR (CDCl3, δ): 8.20 (d, 2H, CH), 7.92 (d, 2H, CH), 5.27 (s + d, JPtH2 = 108 Hz, br, 1H, NH), 3.58 (s + d, JPtH3 = 20 Hz, 6H, S(CH3)2), 3.55 (s + d, JPtH3 = 20 Hz, 6H, S(CH3)2). CP-MAS TOSS 13C{1H} NMR (CDCl3, δ): 161.75 (C(NH)NO), 148.61, 145.56, 135.64, 123.33 (Ar), 45.47 (S(CH3)2), 41.01 (S(CH3)2). Crystals of 4f suitable for X-ray diffraction were obtained by slow evaporation of MeOH solution at RT in air.
Footnote |
† Electronic supplementary information (ESI) available: Characterization and spectra of 3a–b, 3d–f, and 4c–g, X-ray structure determinations and crystal data of 3a–b, 3d–f, 4c, 4f and [2cH][PtCl3(Me2O)], and concentration–effect curves of 3b, 3d–e and 4c–e. CCDC 1475377, 1475378, 1475381, 1475389, 1475399, 1475400, 1475446 and 1475683. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7nj00982h |
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2017 |